Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Bronchodilators Market, by Drug Class
1.4.2 Europe Bronchodilators Market, by Route of Administration
1.4.3 Europe Bronchodilators Market, by Disease
1.4.4 Europe Bronchodilators Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Europe Bronchodilators Market by Drug Class
3.1 Europe Beta-Adrenergic Market by Country
3.2 Europe Xanthine Derivatives Market by Country
3.3 Europe Anticholinergic Market by Country
Chapter 4. Europe Bronchodilators Market by Route of Administration
4.1 Europe Nasal (Inhalable) Market by Country
4.2 Europe Oral Market by Country
4.3 Europe Injectable Market by Country
Chapter 5. Europe Bronchodilators Market by Disease
5.1 Europe Asthma Market by Country
5.2 Europe Chronic Obstructive Pulmonary Disease (COPD) Market by Country
5.3 Europe Others Market by Country
Chapter 6. Europe Bronchodilators Market by Country
6.1 Germany Bronchodilators Market
6.1.1 Germany Bronchodilators Market by Drug Class
6.1.2 Germany Bronchodilators Market by Route of Administration
6.1.3 Germany Bronchodilators Market by Disease
6.2 UK Bronchodilators Market
6.2.1 UK Bronchodilators Market by Drug Class
6.2.2 UK Bronchodilators Market by Route of Administration
6.2.3 UK Bronchodilators Market by Disease
6.3 France Bronchodilators Market
6.3.1 France Bronchodilators Market by Drug Class
6.3.2 France Bronchodilators Market by Route of Administration
6.3.3 France Bronchodilators Market by Disease
6.4 Russia Bronchodilators Market
6.4.1 Russia Bronchodilators Market by Drug Class
6.4.2 Russia Bronchodilators Market by Route of Administration
6.4.3 Russia Bronchodilators Market by Disease
6.5 Spain Bronchodilators Market
6.5.1 Spain Bronchodilators Market by Drug Class
6.5.2 Spain Bronchodilators Market by Route of Administration
6.5.3 Spain Bronchodilators Market by Disease
6.6 Italy Bronchodilators Market
6.6.1 Italy Bronchodilators Market by Drug Class
6.6.2 Italy Bronchodilators Market by Route of Administration
6.6.3 Italy Bronchodilators Market by Disease
6.7 Rest of Europe Bronchodilators Market
6.7.1 Rest of Europe Bronchodilators Market by Drug Class
6.7.2 Rest of Europe Bronchodilators Market by Route of Administration
6.7.3 Rest of Europe Bronchodilators Market by Disease
Chapter 7. Company Profiles
7.1 Glenmark Pharmaceuticals Limited
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Research & Development Expenses
7.1.4 Recent strategies and developments:
7.1.4.1 Product Launches and Product Expansions:
7.2 Merck & Co., Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expenses
7.3 GlaxoSmithKline PLC
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expense
7.4 AstraZeneca PLC
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expenses
7.5 Teva Pharmaceutical Industries Ltd.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional Analysis
7.5.4 Research & Development Expenses
7.6 Cipla Limited
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expense
7.7 Viatris, Inc. (Mylan N.V.)
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.8 Novartis AG
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.9 Boehringer Ingelheim International Gmbh
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Regional & Segmental Analysis
7.9.4 Research & Development Expenses
7.10. Sun Pharmaceutical Industries Ltd.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Regional & Segmental Analysis
7.10.4 Research & Development Expenses
Unique Offerings 